The therapeutic efficacy and application prospects of tumor-treating fields (TTFields) in resolving malignant tumors of central nervous system

被引:0
|
作者
Han, Wei [1 ,2 ,3 ]
Chen, Liang [1 ,2 ,3 ]
机构
[1] Fudan Univ, Neurosurg Dept Huashan Hosp, Shanghai 200032, Peoples R China
[2] Fudan Univ, MOE Frontiers Ctr Brain Sci, Shanghai 200032, Peoples R China
[3] Chen Inst Clin Translat Res Ctr, Tianqiao & Chrissy, Shanghai 200032, Peoples R China
关键词
Tumor-treating fields (TTFields); Central nervous system (CNS); Malignant tumors; Biological mechanisms; Clinic application; IMMUNOGENIC CELL-DEATH; LUNG-CANCER; IN-VITRO; GLIOBLASTOMA; COMBINATION; CHEMOTHERAPY; DISRUPTION; MIGRATION; TRIAL;
D O I
10.1007/s12094-025-03909-x
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
PurposeMalignancies in the central nervous system (CNS) are among the most prevalent and lethal tumors. Tumor treating fields (TTFields), a physical therapeutic strategy, show significant potential in treating CNS tumors by inducing cell apoptosis, cell-cycle arrest, immune activation, and enhancing anti-PD-1 therapy efficacy. Additionally, TTFields can increase blood-brain barrier (BBB) permeability, further supporting their application in CNS malignancies. This review aims to summarize the advances and mechanisms of TTFields in CNS tumor treatment while addressing its current limitations and challenges.MethodsWe reviewed existing literature on TTFields, focusing on their effects on glioma and brain metastasis (BM)-related primary tumors. The mechanisms investigated included mitosis and cell cycle interference, inhibition of cell migration and invasion, promotion of apoptosis and protective autophagy, activation of immunogenic cell death (ICD) and immune responses, and modulation of BBB permeability.ResultsTTFields demonstrate inhibitory effects on CNS malignancies, particularly in glioma. They also suppress brain metastasis from primary tumors such as lung cancer, breast cancer, melanoma, and colorectal cancer. Mechanistically, TTFields act through multiple pathways, including disrupting mitosis, impeding cell migration and invasion, enhancing apoptosis and autophagy, activating immune responses, and increasing BBB permeability.ConclusionTTFields exhibit therapeutic potential in CNS malignancies, especially glioblastoma (GBM), through diverse biological mechanisms. Their ability to enhance BBB permeability and target metastatic tumors suggests promise for broader clinical applications, including brain metastasis treatment.
引用
收藏
页数:11
相关论文
共 6 条
  • [1] Therapeutic potential of tumor treating fields for malignant brain tumors
    Zhou, Youyou
    Xing, Xiaoqing
    Zhou, Jinyun
    Jiang, Han
    Cen, Peili
    Jin, Chentao
    Zhong, Yan
    Zhou, Rui
    Wang, Jing
    Tian, Mei
    Zhang, Hong
    CANCER REPORTS, 2023, 6 (05)
  • [2] Tumor-treating fields (TTFields) induce immunogenic cell death resulting in enhanced antitumor efficacy when combined with anti-PD-1 therapy
    Voloshin, Tali
    Kaynan, Noa
    Davidi, Shiri
    Porat, Yaara
    Shteingauz, Anna
    Schneiderman, Rosa S.
    Zeevi, Einav
    Munster, Mijal
    Blat, Roni
    Tempel Brami, Catherine
    Cahal, Shay
    Itzhaki, Aviran
    Giladi, Moshe
    Kirson, Eilon D.
    Weinberg, Uri
    Kinzel, Adrian
    Palti, Yoram
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2020, 69 (07) : 1191 - 1204
  • [3] Tumor Treating Fields (TTFields) downregulate the Fanconi Anemia-BRCA pathway and increase the efficacy of chemotherapy in malignant pleural mesothelioma preclinical models
    Mumblat, Helena
    Martinez-Conde, Antonia
    Braten, Ori
    Munster, Mijal
    Dor-On, Eyal
    Schneiderman, Rosa S.
    Porat, Yaara
    Voloshin, Tali
    Davidi, Shiri
    Blatt, Roni
    Shteingauz, Anna
    Tempel-Brami, Catherine
    Zeevi, Einav
    Lajterer, Carolina
    Shmueli, Yuval
    Danilov, Shiri
    Haber, Adi
    Giladi, Moshe
    Weinberg, Uri
    Kinzel, Adrian
    Palti, Yoram
    LUNG CANCER, 2021, 160 : 99 - 110
  • [4] Tumor-treating fields (TTFields) induce immunogenic cell death resulting in enhanced antitumor efficacy when combined with anti-PD-1 therapy
    Tali Voloshin
    Noa Kaynan
    Shiri Davidi
    Yaara Porat
    Anna Shteingauz
    Rosa S. Schneiderman
    Einav Zeevi
    Mijal Munster
    Roni Blat
    Catherine Tempel Brami
    Shay Cahal
    Aviran Itzhaki
    Moshe Giladi
    Eilon D. Kirson
    Uri Weinberg
    Adrian Kinzel
    Yoram Palti
    Cancer Immunology, Immunotherapy, 2020, 69 : 1191 - 1204
  • [5] Safety of Tumor Treating Fields (TTFields) therapy in pediatric patients with malignant brain tumors: Post-marketing surveillance data
    Goldman, Stewart
    Margol, Ashley
    Hwang, Eugene I. I.
    Tanaka, Kazuhiro
    Suchorska, Bogdana
    Crawford, John R. R.
    Kesari, Santosh
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [6] Relapse and Outcome Patterns of Patients With Central Nervous System Mixed Malignant Germ Cell Tumors Treated Without Irradiation: Findings From the Third International Central Nervous System (CNS) Germ Cell Tumor (GCT) Study
    Pruitt, Rachel
    DaSilva, Nasjla S.
    Cappellano, Andrea
    Belessiotis, Clara
    Diez, Blanca
    Gardner, Sharon
    Allen, Jeffrey
    Weinblatt, Mark
    Gottardo, Nicholas
    Dhall, Girish
    Finlay, Jonathan L.
    PEDIATRIC BLOOD & CANCER, 2015, 62 (11) : 1920 - 1924